The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap

References

• World Health Organization. Global Tuberculosis Report 2016. Geneva, Switzerland: WHO; 2016.
   Google Scholar
• Donald PR. Childhood tuberculosis: the hidden epidemic. Int J Tuberc Lung Dis. 2004;8(5):627–629.
   PubMed Web of Science ®Google Scholar
• Lestari T, Probandari A, Hurtig A-K, et al. High caseload of childhood tuberculosis in hospitals on Java Island, Indonesia: a cross-sectional study. BMC Public Health. 2011;11:784.
   PubMed Web of Science ®Google Scholar
• Graham SM, Sismanidis C, Menzies HJ, et al. Importance of tuberculosis control to address child survival. Lancet. 2014;383:1605–1607.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. second edition. Geneva, Switzerland: WHO; 2014.
   Google Scholar
• World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland: WHO; 2015.
   Google Scholar
• Hill PC, Rutherford ME, Audas R. van CR, Graham SM. Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries. Plos Med. 2011;8:e1001105.
   Google Scholar
• Graham SM, Triasih R. More evidence to support screening of child contacts of tuberculosis cases: if not now, then when? Clin Infect Dis. 2013;57:1693–1694.
   PubMed Web of Science ®Google Scholar
• Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(3):392–402.
   PubMed Web of Science ®Google Scholar
• Drobac PC, Shin SS, Huamani P, et al. Risk factors for in-hospital mortality among children with tuberculosis: the 25-year experience in Peru. Pediatrics. 2012;130:e373–e379.
   PubMed Web of Science ®Google Scholar
• Munoz-Sellart M, Yassin MA, Tumato M, et al. Outcome of children with tuberculosis in southern Ethiopia. Scand J Infect Dis. 2009;41(6–7):450–455.
   PubMed Web of Science ®Google Scholar
• Jaganath D, Zalwango S, Okware B, et al. Contact investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis. 2013;57:1685–1692.
   PubMed Web of Science ®Google Scholar
• Fox GJ, Barry SE, Britton WJ, et al. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41:140–156.
   PubMed Web of Science ®Google Scholar
• Gomes VF, Andersen A, Wejse C, et al. Impact of tuberculosis exposure at home on mortality among children less than 5 years old in Guinea Bissau. Thorax. 2011;66(2):163–167.
   PubMed Web of Science ®Google Scholar
• Du Preez K, Hesseling AC, Mandalakas AM, et al. Opportunities for chemoprophylaxis in children with culture-confirmed tuberculosis. Ann Trop Paed Int Child Health. 2011;31:301–310.
   PubMed Web of Science ®Google Scholar
• Donald PR. Edith Lincoln, an American pioneer of childhood tuberculosis. Pediatr Infect Dis J. 2013;32:241–245.
   PubMed Web of Science ®Google Scholar
• Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.
   PubMedGoogle Scholar
• Hsu KH. Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents. Jama. 1984;251:1283–1285.
   PubMed Web of Science ®Google Scholar
• Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;2:CD001363.
   Google Scholar
• Cruz AT, Ahmed A, Mandalakas AM, et al. Treatment of latent tuberculosis infection in children. J Pediatr Infect Dis Soc. 2013;2(3):248–258.
   PubMedGoogle Scholar
• Yuen CM, Jenkins HE, Rodriguez CA, et al. Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics. 2015;136(1):e50–e59.
   PubMed Web of Science ®Google Scholar
• Triasih R, Duke T, Robertson C, et al. A prospective evaluation of the symptom-based screening approach to the management of children that are contacts of tuberculosis cases. Clin Infect Dis. 2015;60:12–18.
   PubMed Web of Science ®Google Scholar
• Adjobimey M, Masserey E, Adjonou C, et al. Implementation of isoniazid preventive therapy in children aged under 5 years exposed to tuberculosis in Benin. Int J Tuberc Lung Dis. 2016;20(8):1055–1059.
   PubMed Web of Science ®Google Scholar
• Maritz ER, Montepiedra G, Liu L, et al. Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study. Int J Tuberc Lung Dis. 2016;20(8):1060–1064.
   PubMed Web of Science ®Google Scholar
• Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532–1549.
   PubMed Web of Science ®Google Scholar
• Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis. 2009;48:108–114.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for intensified case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO; 2011.
   Google Scholar
• World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, Switzerland: WHO; 2014.
   Google Scholar
• World Health Organization. Latent Tuberculosis Infection Taskforce terms of reference. Geneva, Switzerland: WHO; 2015. cited 2016 July 1st. Available from: www.who.int/tb/challenges/task_force/en/-
   Google Scholar
• World Health Organization. Report of the global consultation on the programmatic management of latent tuberculosis infection. Seoul, Republic of Korea. Geneva, Switzerland: WHO; 2016 cited 2016 April 27-28
   Google Scholar
• Stop TB Partnership. The paradigm shift 2016-2020. The Global Plan to End TB. Geneva, Switzerland: Stop TB Partnership; 2016.
   Google Scholar
• WHO/IUATLD/CDC/UNICEF/TAG/USAID. Roadmap for childhood tuberculosis: towards zero deaths. Geneva, Switzerland: WHO; 2013.
   Google Scholar
• Kruk A, Gie RP, Schaaf HS, et al. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics. 2008;121(6):e1646–e1652.
   Google Scholar
• Rutherford ME, Hill PC, Triasih R, et al. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health. 2012;17:1264–1273.
   PubMed Web of Science ®Google Scholar
• Hall C, Sukijthamapan P, Dos Santos R, et al. Challenges to delivery of isoniazid preventive therapy in a cohort of children exposed to tuberculosis in Timor-Leste. Trop Med Int Health. 2015;20(6):730–736.
   PubMed Web of Science ®Google Scholar
• Rutherford ME, Ruslami R, Anselmo M, et al. Management of children exposed to Mycobacterium tuberculosis: a public health evaluation in West Java, Indonesia. Bull World Health Organ. 2013;91(12):932–994.
   PubMed Web of Science ®Google Scholar
• Triasih R, Robertson C, De Campo J, et al. An evaluation of chest X-ray in the context of community-based screening of child tuberculosis contacts. Int J Tuberc Lung Dis. 2015;19:1428–1434.
   PubMed Web of Science ®Google Scholar
• Mandalakas AM, Hesseling AC, Gie RP, et al. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax. 2013;68(3):247–255.
   PubMed Web of Science ®Google Scholar
• Rekha B, Jagarajamma K, Chandrasekaran V, et al. Improving screening and chemoprophylaxis among child contacts in India’s RNTCP: a pilot study. Int J Tuberc Lung Dis. 2013;17(2):163–168.
   PubMed Web of Science ®Google Scholar
• Tadesse Y, Gebre N, Daba S, et al. Uptake of isoniazid preventive therapy among under-five children: TB contact investigation as an entry point. Plos ONE. 2016;11(5):e0156525.
   Google Scholar
• Gomes VF, Wejse C, Oliveira I, et al. Adherence to isoniazid preventive therapy in children exposed to tuberculosis: a prospective study from Guinea-Bissau. Int J Tuberc Lung Dis. 2011;15(12):1637–1643.
   PubMed Web of Science ®Google Scholar
• Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16.
   PubMedGoogle Scholar
• Lobato MN, Jereb JA, Starke JR. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics. 2008;121(6):e1732–1733.
   Google Scholar
• Garie KT, Yassin MA, Cuevas LE. Lack of adherence to isoniazid chemoprophylaxis in children in contact with adults with tuberculosis in Southern Ethiopia. Plos ONE. 2011;6:e26452.
   PubMed Web of Science ®Google Scholar
• Marais BJ, Van Zyl S, Schaaf HS, et al. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child. 2006;91:762–765.
   PubMed Web of Science ®Google Scholar
• Triasih R, Padmawati RS, Duke T, et al. A mixed-methods evaluation of adherence to preventive treatment among child tuberculosis contacts in Indonesia. Int J Tuberc Lung Dis. 2016;20(8):1078–1083.
   PubMed Web of Science ®Google Scholar
• Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119:827–830.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166.
   PubMed Web of Science ®Google Scholar
• Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247–255.
   PubMed Web of Science ®Google Scholar
• Bliven-Sizemore EE, Sterling TR, Shang N, et al. Thee months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19(9):1039–1044.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. Aids. 2016;30(10):1607–1615.
   PubMed Web of Science ®Google Scholar
• Cruz AT, Starke JR. Safety and adherence for 12 weekly doses of isoniazid and rifapentine for pediatric tuberculosis infection. Pediatr Infect Dis J. 2016;35(7):811–813.
   PubMed Web of Science ®Google Scholar
• Weiner M, Savic RM, Menzie WR, et al. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–145.
   PubMedGoogle Scholar
• Shepardson D, Marks SM, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculosis infection in the United States. Int J Tuberc Lung Dis. 2013;17(12):1531–1537.
   PubMed Web of Science ®Google Scholar
• Bright-Thomas R, Nandwani S, Smith J, et al. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child. 2010;95:600–602.
   PubMed Web of Science ®Google Scholar
• Detjen A, Macé C, Perrin C, et al. Adoption of revised dosage recommendations for childhood tuberculosis in countries with different childhood tuberculosis burdens. Public Health Action. 2012;2(4):126–132.
   PubMedGoogle Scholar
• Wang J-Y, Yang P-C. Does a rifamycin-containing preventive regimen increase rifampicin resistance? An unresolved concern. Int J Tuberc Lung Dis. 2016;20:998.
   PubMed Web of Science ®Google Scholar
• Balcells ME, Thomas SL, Godfrey-Faucett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12:744–751.
   PubMed Web of Science ®Google Scholar
• Den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculosis infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065–1071.
   PubMed Web of Science ®Google Scholar
• Yuen CM, Jenkins HE, Chang R, et al. Two methods for seting child-focused tuberculosis care targets. Public Health Action. 2016;6(2):83–96.
   PubMed Web of Science ®Google Scholar
• Pai M, Sotgiu G. Diagnostics for latent TB infection: incremental, not transformative progress. Eur Resp J. 2016;47:704–706.
   PubMed Web of Science ®Google Scholar
• Tebruegge M, Dutta B, Donath S, et al. Mycobacteria-specific cytokine responses detect TB infection and distinguish latent from active TB. Am J Resp Crit Care Med. 2015;192:485–492.
   PubMed Web of Science ®Google Scholar
• Nicol MP, Gnanashanmugam D, Browning R, et al. A blueprint to address research gaps in the development of biomarkers for pediatric TB. Clin Infect Dis. 2015;61(suppl3):S164–S172.
   Google Scholar
• Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387(10035):2312–2322.
   PubMed Web of Science ®Google Scholar
• Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M.tuberculosis infection. Plos One. 2013;8:e64215.
   PubMed Web of Science ®Google Scholar
• Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Resp J. 2016;47:919–928.
   PubMed Web of Science ®Google Scholar
• Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193–1201.
   PubMed Web of Science ®Google Scholar
• Harausz E, Garcia-Prats AJ, Schaaf HS, et al. Global treatment outcomes in children with paediatric MDR-TB: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(suppl 2):S29.
   Google Scholar
• Seddon JA, Fred D, Amanullah F, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Policy brief no. 1. Dubai, United Arab Emirates: Harvard Medical School Center for Global Health Delivery, Dubai; 2015.
   Google Scholar
• Seddon JA, Hesseling AC, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis. 2013;57(12):1676–1684.
   PubMed Web of Science ®Google Scholar
• Bamrah S, Brostrom R, Fred D, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014;18(8):912–918.
   PubMed Web of Science ®Google Scholar
• Graham SM, Grzemska M, Brands A, et al. Regional initiatives to address the challenges of tuberculosis in children: perspectives from the Asia-Pacific region. Int J Infect Dis. 2015;32:166–169.
   PubMed Web of Science ®Google Scholar
• International Union Against Tuberculosis and Lung Disease. Childhood TB Learning Portal. Paris, France: The Union; 2016. Available from: https://childhoodtb.theunion.org/
   Google Scholar
• World Health Organization. Childhood TB: Training Toolkit. Geneva, Switzerland: WHO; Available from: http://www.who.int/tb/challenges/childtbtraining_manual/en/
   Google Scholar